Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Cognitive impairment without dementia is associated with increased risk for disability, increased health care costs, and progression to dementia. There are no population-based prevalence estimates of this condition in the United States. Objective To estimate the prevalence of cognitive impairment without dementia in the United States and determine longitudinal cognitive and mortality outcomes. Design Longitudinal study from July 2001 to March 2005. Setting In-home assessment for cognitive impairment. Participants Participants in ADAMS (Aging, Demographics, and Memory Study) who were age 71 years or older drawn from the nationally representative HRS (Health and Retirement Study). Of 1770 selected individuals, 856 completed initial assessment, and of 241 selected individuals, 180 completed 16- to 18-month follow-up assessment. Measurements Assessments, including neuropsychological testing, neurologic examination, and clinical and medical history, were used to assign a diagnosis of normal cognition, cognitive impairment without dementia, or dementia. National prevalence rates were estimated by using a population-weighted sample. Results In 2002, an estimated 5.4 million people (22.2%) in the United States age 71 years or older had cognitive impairment without dementia. Prominent subtypes included prodromal Alzheimer disease (8.2%) and cerebrovascular disease (5.7%). Among participants who completed follow-up assessments, 11.7% with cognitive impairment without dementia progressed to dementia annually, whereas those with subtypes of prodromal Alzheimer disease and stroke progressed at annual rates of 17% to 20%. The annual death rate was 8% among those with cognitive impairment without dementia and almost 15% among those with cognitive impairment due to medical conditions. Limitations Only 56% of the nondeceased target sample completed the initial assessment. Population sampling weights were derived to adjust for at least some of the potential bias due to nonresponse and attrition. Conclusion Cognitive impairment without dementia is more prevalent in the United States than dementia, and its subtypes vary in prevalence and outcomes.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. The estimates come from a sample in which only 56% took part, describe people 71 and older in 2002, and say nothing about causes or treatment. Reported effect size: 22.2%; 8.2%; 5.7%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., et al. (2008). Prevalence of cognitive impairment without dementia in the United States. Annals of internal medicine. https://doi.org/10.7326/0003-4819-148-6-200803180-00005

Vancouver

Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of cognitive impairment without dementia in the United States. Annals of internal medicine. 2008. doi:10.7326/0003-4819-148-6-200803180-00005. PMID: 18347351.

BibTeX

@article{plassman2008-18347351,
  author  = {Plassman, B. L. and Langa, K. M. and Fisher, G. G. and Heeringa, S. G. and Weir, D. R. and Ofstedal, M. B. and Burke, JR. and Hurd, M. D. and others},
  title   = {{Prevalence of cognitive impairment without dementia in the United States}},
  journal = {Annals of internal medicine},
  year    = {2008},
  doi     = {10.7326/0003-4819-148-6-200803180-00005},
  pmid    = {18347351},
  url     = {https://doi.org/10.7326/0003-4819-148-6-200803180-00005}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Using in-home assessments of a nationally representative sample, this study estimated that "5.4 million people (22.2%) in the United States age 71 years or older had cognitive impairment without dementia" in 2002, and concluded the condition "is more prevalent in the United States than dementia." Among those followed up, 11.7% a year progressed to dementia, rising to 17% to 20% for the prodromal Alzheimer disease and stroke subtypes. The estimates come from a sample in which only 56% took part, describe people 71 and older in 2002, and say nothing about causes or treatment.

Study details

How this study scored 67/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 64 of the 96 points it could be judged on, which is 67 of 100. Total 67 of 100.64 of the 96 points we could judge = 67 of 100

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of internal medicine)
Journal's citation record 4 / 4 Annals of Internal Medicine: journal h-index 648 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 933 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 46.6 citations a year over 20 year(s) since 2008
Impact for its field and year 5 / 6 Cited 29.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 47 other studies in this library
Still being cited 3 / 4 Cited 89 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of Michigan: institution h-index 2,240 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 18347351)
Free to read 0 / 2 Behind a paywall — scores zero
Points 64 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100.
Total 67 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Later studies that cite this one

47 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →